Compare STRT & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRT | RCKT |
|---|---|---|
| Founded | 1908 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.4M | 239.3M |
| IPO Year | 1996 | 2014 |
| Metric | STRT | RCKT |
|---|---|---|
| Price | $60.35 | $2.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $8.58 |
| AVG Volume (30 Days) | 45.9K | ★ 2.2M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.17 | ★ 26.37 |
| EPS | ★ 5.00 | 0.66 |
| Revenue | ★ $439,195,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.24 | $915.60 |
| P/E Ratio | $12.13 | ★ $3.50 |
| Revenue Growth | ★ 5.24 | N/A |
| 52 Week Low | $57.01 | $2.17 |
| 52 Week High | $93.00 | $5.45 |
| Indicator | STRT | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 31.54 | 37.77 |
| Support Level | $57.01 | N/A |
| Resistance Level | $83.87 | $3.70 |
| Average True Range (ATR) | 1.74 | 0.18 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 18.55 | 18.70 |
Strattec Security Corp designs automotive access company that designs and delivers safe, secure, and engineered access solutions for the automotive and mobility markets. Built on generations of access and security engineering expertise, partner closely with OEMs to create differentiated, system level access experiences for end consumers. Its product portfolio spans the access journey from Permission, enabling secure vehicle entry through advanced mechanical and electronic systems; to Motion, delivering effortless, reliable powered access that enhances everyday usability; and through to Hold, providing precision engineered latching solutions.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.